Is Viridian Therapeutics, Inc. overvalued?

Viridian Therapeutics, Inc. (VRDN) — key valuation metrics and fundamentals.

No verdict

Price

$22.07

Fair value

—

Current P/E

—

Normal P/E

—

Market cap

$2.50B

Dividend yield

0.0%

Return on equity

-61.3%

Sector

Healthcare

Fair value compares VRDN's current P/E to its own historical "normal" P/E (FAST Graphs-style). Updated 11 Aug 2026.

Related stocks